secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001564590-22-007361
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology reports Q4 2021 net loss $28.4M ($0.70/shr); cash $363.7M through mid-2024
--------------------------------------------------------------------------------

- GAAP net loss Q4 2021: $28.4M ($0.70/shr) vs $18.8M ($0.50/shr) year ago; full year loss $83.5M ($2.07/shr).
- R&D expenses Q4 $20.9M (incl. $4.7M ScalmiBio acquisition IPR&D) vs $12.1M year ago.
- Cash $363.7M at Dec 31, 2021; runway through mid-2024.
- FDA granted Orphan Drug Designation for evorpacept in gastric/GEJ cancer (Jan 2022).
- Plan to initiate randomized Phase 2/3 ASPEN-06 trial in 2nd line gastric/GEJ cancer in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000156459022007361/0001564590-22-007361-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000156459022007361/alxo-8k_20220228.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-007361

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer